These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 12528092

  • 1. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG.
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 3. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ, Zhang X, Zhu WL, Huang Y.
    Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324
    [Abstract] [Full Text] [Related]

  • 4. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
    Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E, Kortsaris A, Hatseras D.
    Eur Cytokine Netw; 2004 Jun 27; 15(3):231-9. PubMed ID: 15542448
    [Abstract] [Full Text] [Related]

  • 5. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
    Am Heart J; 2005 Sep 27; 150(3):484-7. PubMed ID: 16169329
    [Abstract] [Full Text] [Related]

  • 6. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
    Jordán A, Roldán V, García M, Monmeneu J, de Burgos FG, Lip GY, Marín F.
    J Intern Med; 2007 Sep 27; 262(3):385-92. PubMed ID: 17697160
    [Abstract] [Full Text] [Related]

  • 7. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG.
    Circulation; 2006 Sep 05; 114(10):1020-7. PubMed ID: 16923753
    [Abstract] [Full Text] [Related]

  • 8. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J.
    Tuberculosis (Edinb); 2001 Sep 05; 81(3):203-9. PubMed ID: 11466032
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP, Moyssakis I, Makris TK, Poulakou M, Stavroulakis G, Perrea D, Votteas VE.
    Eur Cytokine Netw; 2005 Jun 05; 16(2):152-60. PubMed ID: 15941687
    [Abstract] [Full Text] [Related]

  • 10. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D.
    Arthritis Rheum; 2004 Sep 05; 50(9):2942-53. PubMed ID: 15457463
    [Abstract] [Full Text] [Related]

  • 11. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.
    Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J.
    J Card Fail; 2006 Feb 05; 12(1):66-72. PubMed ID: 16500583
    [Abstract] [Full Text] [Related]

  • 12. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 13. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI.
    Int J Cardiol; 2004 Apr 15; 94(2-3):269-77. PubMed ID: 15093992
    [Abstract] [Full Text] [Related]

  • 14. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V, Halvorsen B, Damås JK, Nordøy I, Yndestad A, Aukrust P, Frøland SS.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1659-63. PubMed ID: 15547092
    [Abstract] [Full Text] [Related]

  • 15. [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion].
    Moche M, Hui DS, Huse K, Chan KS, Choy DK, Scholz GH, Gosse H, Winkler J, Schauer J, Sack U, Hoheisel G.
    Pneumologie; 2005 Aug 15; 59(8):523-8. PubMed ID: 16110415
    [Abstract] [Full Text] [Related]

  • 16. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J.
    J Crit Care; 2011 Dec 15; 26(6):550-5. PubMed ID: 21530151
    [Abstract] [Full Text] [Related]

  • 17. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY, Wu TC, Lin WT, Leu HB, Lin CP, Lin SJ, Chen JW.
    Eur J Clin Invest; 2006 Feb 15; 36(2):76-84. PubMed ID: 16436088
    [Abstract] [Full Text] [Related]

  • 18. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.
    Rheumatology (Oxford); 2006 Apr 15; 45(4):414-20. PubMed ID: 16287916
    [Abstract] [Full Text] [Related]

  • 19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb 15; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

  • 20. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 15; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.